> Boehringer Ingelheim and Zealand Pharma moved dual-acting GLP-1/glucagon agonist BI 456906 into a phase 2 trial in diabetes and obesity. The start of the trial will trigger a €20 million ($22 million) milestone payment to Zealand. Release
> UniQure’s pivotal hemophilia B gene therapy trial hit its enrollment target. UniQure plans to continue adding up to six patients throughout September, taking it above the target. Statement
> Valo Therapeutics acquired oncolytic virus technology from the University of Helsinki. Release
> Macrophage Pharma named Søren Bregenholt as its CEO. Bregenholt previously held senior roles at Symphogen and IO Biotech. Statement
> Gyroscope Therapeutics raised £50.4 million ($60.6 million) to fund clinical development of a dry age-related macular degeneration gene therapy. Syncona provided most of the money. Release (PDF)